title: Recent advances and novel agents for gastrointestinal stromal tumor (GIST).
abstract: The discovery of CD117 mutation in almost all gastrointestinal stromal tumors (GISTs) marked a milestone. Other spindle cell neoplasms arising from the GI tract including lipoma, schwannoma, hemangioma, leiomyoma, and leiomyosarcoma are typically CD117-negative. GIST research and clinical care now represent a paradigm of translating discoveries in the molecular pathogenesis of cancer into highly effective targeted therapies that selectively inhibit etiologic "driver" pathways, leading to dramatically improved clinical outcomes. A series of investigations and trials are underway to develop novel and effective ways to treat patients with GIST. In this review, we discuss the highlights of recent advances and novel agents for GIST therapy.
authors.affiliation: Division of Oncology/Hematology, New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USA.
authors.forename: Gurpreet
authors.initials: G
authors.lastname: Lamba
authors.forename: Samir
authors.initials: S
authors.lastname: Ambrale
authors.forename: Byung
authors.initials: B
authors.lastname: Lee
authors.forename: Ridhi
authors.initials: R
authors.lastname: Gupta
authors.forename: Shamudheen M
authors.initials: SM
authors.lastname: Rafiyath
authors.forename: Delong
authors.initials: D
authors.lastname: Liu
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000378:metabolism*; D006801:Humans; D058990:Molecular Targeted Therapy
chemical_list: D000970:Antineoplastic Agents